PRAXIS PRECISION MEDICINES I

$4.66 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About PRAXIS PRECISION MEDICINES I

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating genetic insights into the development of therapies for central nervous system (CNS) disorders. Its portfolio of CNS programs is structured by therapeutic focus in three primary franchises, which include Psychiatry, Movement Disorders, and Epilepsy. It has three product candidates, which include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extra synaptic gamma-aminobutyric acid-A (GABAA) receptor preferring positive allosteric modulator (PAM) for the treatment of a range of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channels developed for the treatment of Essential Tremor (ET) and Parkinson's Disease(PD). PRAX-114 is developed for the treatment of a range of patients suffering from post-traumatic stress disorder (PTSD).

Stock Analysis

last close $4.66
1-mo return 30.2%
3-mo return -55%
avg daily vol. 665.9T
52-week high 23.56
52-week low 1.63
market cap. $199M
forward pe -
annual div. -
roe -98.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe